Skip to content

Static Helical Screw Locking of Pertrochanteric Femur Fractures Using the TFN-A

Static Helical Screw Locking of Pertrochanteric Femur Fractures Using the TFN-Advanced Proximal Femoral Nailing System - a Randomized Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04851509
Acronym
TFN-A
Enrollment
218
Registered
2021-04-20
Start date
2021-05-17
Completion date
2027-01-31
Last updated
2025-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pertrochanteric Fracture

Brief summary

The study will investigate the shortening and collapse of pertrochanteric fractures following surgical management with the TFN-Advanced nailing system. The focus will be on comparing radiographic assessments of nails which have been statically locked versus dynamically locked. This is a randomized control study with the initial invention being randomized to either statically locking or dynamically locking. For a two-month period, all eligible patients will receive the randomized allocated treatment, then treatment will switch to the alternate treatment for the next two months and will continue to alternate treatments for two-month periods until study enrollment has completed.

Detailed description

Hip fractures are common injuries in the elderly population that result in significant morbidity and mortality and a significant burden on health care systems. Hip fractures can be treated with arthroplasty or with internal fixation, depending on the fracture pattern. Cephalomedullary nailing (CMN) has become one of the established treatments for intertrochanteric hip fractures with a wide variety of implant designs from many different companies. The TFN-ADVANCED™ Proximal femoral nailing system (TFN-A) is a novel implant for treating intertrochanteric and subtrochanteric proximal femur fractures with a paucity of published literature on the performance of this implant. A method to decrease the amount of fracture compression is to use the set screw to lock the screw statically so it does not slide to the same degree as if the screw is placed in the dynamic or sliding position. To the knowledge of the investigators, the role of statically locking the screw to prevent fracture collapse has not been studied. Statically locking CMN to treat hip fractures has become standard of care at the Royal Columbian Hospital with all the investigating surgeons having adopted this practice in an attempt to prevent significant fracture collapse and neck shortening. Anecdotally, the investigators have not seen significant rates of cephalic screw cut-out over the past five years, and believe the investigators' screw cut-out rates are lower than what is reported in the literature. The investigators have been using the Gamma Nail (Stryker) to statically lock the screw as the previous TFN lacked the ability for static locking. However, with the advent of the TFN-A, the investigators have adopted this implant as their long cephalomedullary nail of choice for fixation of pertrochanteric femur fractures.

Interventions

PROCEDUREDynamic Rotational Locking

Performed, as per the Synthes technique guide, using the 5mm hex flexible set screwdriver and then loosening the set screw by one-half turn of the screwdriver.

PROCEDUREStatic Locking

Performed by using the torque-limiting set screwdriver and locking the set screw down onto the helical screw to prevent dynamic sliding of the screw within the nail.

Sponsors

DePuy Synthes
CollaboratorINDUSTRY
Fraser Orthopaedic Research Society
Lead SponsorNETWORK

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Surgeons cannot be blinded to the treatment allocation of the surgical intervention due to having to perform the static or dynamic rotational lock. Participants will be blinded to the form of locking they receive. Research personnel completing the outcome measures will be blinded. Data analyst(s) and the radiographic reviewer(s) will be blinded to the treatment arm.

Intervention model description

Randomized trial design utilizing alternating treatment allocation to assign patients to treatment arms, treatment allocations will last for two months at a time.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \>18 years of age * AO/OTA 31-A fractures who the surgeon deems eligible for treatment with a cephalomedullary nail * Open and closed fractures * Ambulatory prior to injury (with or without walking aides) * Native (non-fractured, no implant) contralateral hip * Willing and able to sign consent (substitute decision maker)

Exclusion criteria

* Contralateral hip fracture or hip arthroplasty * Fracture not amenable to treatment with a cephalomedullary nail * Non-ambulatory patient * Fractures \>14 days (time of injury to OR) * Bilateral pertrochanteric hip fractures * Non-unions * Pathologic fractures * Periprosthetic fractures * Patients with spinal injury * Incarceration * Pregnancy * Limited life expectancy due to significant medical co-morbidities or medical contra-indications to surgery * Likely problems, in the judgement of the investigators, with maintaining follow-up (i.e., patients with no fixed address, report a plan to move out of town, or intellectually challenged patients without adequate family support).

Design outcomes

Primary

MeasureTime frameDescription
Radiographic Assessment12 months post treatmentThe primary objective of this study will be to investigate how statically locking the TFN-A influences shortening or collapse of pertrochanteric fractures by measuring radiographic shortening or collapse of pertrochanteric fractures treated with the TFN-A implant.

Secondary

MeasureTime frameDescription
Fracture Reduction QualityIntra-operativelyAssessed through x-rays of the entire proximal femur
Femoral Offset1 day post-op, 6 weeks, 12 weeks, 6 months, and 12 monthsMeasured in a method described by O. Paul et al
Tip-Apex distance1 day post-op, 6 weeks, 12 weeks, 6 months, and 12 monthsMeasured as described by Baumgaertner et al
Complicationsintra-operatively, 1 day post-op, 6 weeks, 12 weeks, 6 months, and 12 monthsSAEs/AEs

Countries

Canada

Contacts

Primary ContactKyrsten Butterfield, BSc
kyrsten.butterfield@fraserhealth.ca604-553-3247

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026